{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:08:26Z","timestamp":1792080506599,"version":"4.4.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Phayao and Thailand Science Research and Innovation Fund","award":["Fundamental Fund 2024"],"award-info":[{"award-number":["Fundamental Fund 2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40264-024-01476-8","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T16:02:51Z","timestamp":1725033771000},"page":"25-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Effectiveness and Safety of Off-Label Underdosed Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-1557","authenticated-orcid":false,"given":"Pajaree","family":"Mongkhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noppaket","family":"Singkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyarat","family":"Ponok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natpatsorn","family":"Liamsrijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wipada","family":"Phoosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirayut","family":"Phattanasobhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vichai","family":"Senthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"1476_CR1","unstructured":"Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright\u00a9 2023, StatPearls Publishing LLC.; 2023."},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.str.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138. https:\/\/doi.org\/10.1161\/01.str.22.8.983.","journal-title":"Stroke"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/cir.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071\u2013104. https:\/\/doi.org\/10.1161\/cir.0000000000000040.","journal-title":"Circulation"},{"key":"1476_CR5","unstructured":"Patel S SR, Preuss CV, et al. Warfarin. [Updated 2023 Mar 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470313\/"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/s0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)62343-0.","journal-title":"Lancet"},{"key":"1476_CR11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","volume":"40","author":"KL Wang","year":"2019","unstructured":"Wang KL, Lopes RD, Patel MR, B\u00fcller HR, Tan DS, Chiang CE, et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019;40:1492\u2013500. https:\/\/doi.org\/10.1093\/eurheartj\/ehy802.","journal-title":"Eur Heart J"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/clc.22568","volume":"39","author":"V Aggarwal","year":"2016","unstructured":"Aggarwal V, Armstrong EJ, Liu W, Maddox TM, Ho PM, Carey E, et al. Prasugrel use following PCI and associated patient outcomes: insights from the national VA CART program. Clin Cardiol. 2016;39:578\u201384. https:\/\/doi.org\/10.1002\/clc.22568.","journal-title":"Clin Cardiol"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.joa.2016.11.003","volume":"33","author":"Y Okumura","year":"2017","unstructured":"Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF registry. J Arrhythm. 2017;33:289\u201396. https:\/\/doi.org\/10.1016\/j.joa.2016.11.003.","journal-title":"J Arrhythm."},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597\u2013604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.966.","journal-title":"J Am Coll Cardiol"},{"key":"1476_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1253\/circj.CJ-18-0991","volume":"83","author":"N Murata","year":"2019","unstructured":"Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF registry. Circ J. 2019;83:727\u201335. https:\/\/doi.org\/10.1253\/circj.CJ-18-0991.","journal-title":"Circ J"},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2022.09.073","volume":"371","author":"W Xu","year":"2023","unstructured":"Xu W, Lv M, Wu T, Huang N, Zhang W, Su J, et al. Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: a new evidence of Asian dose. Int J Cardiol. 2023;371:184\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2022.09.073.","journal-title":"Int J Cardiol"},{"key":"1476_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1160\/th10-04-0232","volume":"104","author":"D Capodanno","year":"2010","unstructured":"Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471\u201384. https:\/\/doi.org\/10.1160\/th10-04-0232.","journal-title":"Thromb Haemost"},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jacc.2009.04.084","volume":"54","author":"F Mar\u00edn","year":"2009","unstructured":"Mar\u00edn F, Gonz\u00e1lez-Conejero R, Capranzano P, Bass TA, Rold\u00e1n V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54:1041\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.084.","journal-title":"J Am Coll Cardiol"},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","volume":"40","author":"TF Chao","year":"2019","unstructured":"Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019;40:1518\u201327. https:\/\/doi.org\/10.1093\/eurheartj\/ehy807.","journal-title":"Eur Heart J"},{"key":"1476_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.774109","volume":"8","author":"X Kong","year":"2021","unstructured":"Kong X, Zhu Y, Pu L, Meng S, Zhao L, Zeng W, et al. Efficacy and safety of non-recommended dose of new oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8: 774109. https:\/\/doi.org\/10.3389\/fcvm.2021.774109.","journal-title":"Front Cardiovasc Med."},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/clc.23586","volume":"44","author":"X Liu","year":"2021","unstructured":"Liu X, Huang M, Ye C, Xiao X, Yan C. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: a meta-analysis. Clin Cardiol. 2021;44:472\u201380. https:\/\/doi.org\/10.1002\/clc.23586.","journal-title":"Clin Cardiol"},{"key":"1476_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","volume":"362","author":"MQ Pereira","year":"2022","unstructured":"Pereira MQ, David C, Almeida AG, Brito D, Pinto FJ, Caldeira D. Clinical effects of off-label reduced doses of direct oral anticoagulants: a systematic review and meta-analysis. Int J Cardiol. 2022;362:76\u201382. https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.062.","journal-title":"Int J Cardiol"},{"key":"1476_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.724301","volume":"8","author":"X Wu","year":"2021","unstructured":"Wu X, Hu L, Liu J, Gu Q. Off-label underdosing or overdosing of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Front Cardiovasc Med. 2021;8: 724301. https:\/\/doi.org\/10.3389\/fcvm.2021.724301.","journal-title":"Front Cardiovasc Med."},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","volume":"109","author":"C Valeria","year":"2023","unstructured":"Valeria C, Joris RdG, Marcelo Sanmartin F, Tom\u00e1s S, Carina B-L, David H, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109:178. https:\/\/doi.org\/10.1136\/heartjnl-2022-321114.","journal-title":"Heart"},{"key":"1476_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002197","author":"LPT Joosten","year":"2023","unstructured":"Joosten LPT, van Maanen R, van den Dries CJ, Rutten FH, Hoes AW, Granger CB, et al. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2023. https:\/\/doi.org\/10.1136\/openhrt-2022-002197.","journal-title":"Open Heart."},{"key":"1476_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.121.007971","volume":"14","author":"XL Zhang","year":"2021","unstructured":"Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021;14: e007971. https:\/\/doi.org\/10.1161\/circoutcomes.121.007971.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1476_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.645479","volume":"12","author":"NN Shen","year":"2021","unstructured":"Shen NN, Zhang C, Wang N, Wang JL, Gu ZC, Han H. Effectiveness and safety of under or over-dosing of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 148909 patients from 10 real-world studies. Front Pharmacol. 2021;12: 645479. https:\/\/doi.org\/10.3389\/fphar.2021.645479.","journal-title":"Front Pharmacol"},{"key":"1476_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology\u2014a proposal for reporting. JAMA. 2000;283:2008\u201312. https:\/\/doi.org\/10.1001\/jama.283.15.2008.","journal-title":"JAMA"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"EP Europace."},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1161\/CIR.0000000000000477","volume":"135","author":"AN Raval","year":"2017","unstructured":"Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135:e604\u201333. https:\/\/doi.org\/10.1161\/CIR.0000000000000477.","journal-title":"Circulation"},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.cj-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study. Circ J. 2012;76:2104\u201311. https:\/\/doi.org\/10.1253\/circj.cj-12-0454.","journal-title":"Circ J"},{"key":"1476_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1476_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1476_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.socscimed.2017.05.049","volume":"186","author":"E Shor","year":"2017","unstructured":"Shor E, Roelfs D, Vang ZM. The \u201cHispanic mortality paradox\u201d revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants\u2019 mortality. Soc Sci Med. 2017;186:20\u201333. https:\/\/doi.org\/10.1016\/j.socscimed.2017.05.049.","journal-title":"Soc Sci Med"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690\u20131. https:\/\/doi.org\/10.1001\/jama.280.19.1690.","journal-title":"JAMA"},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"1476_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods."},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"1476_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajmo.2023.100058","volume":"10","author":"A Alayyat","year":"2023","unstructured":"Alayyat A, Zaqqa M, Hammoudeh A, Jaarah D, Bahhour M, Nawaiseh M, et al. Clinical features and impact on one year prognosis of prescribing low doses of direct oral anticoagulant agents in a middle eastern population with atrial fibrillation: analysis from the Jordan atrial fibrillation study. Am J Med Open. 2023;10: 100058. https:\/\/doi.org\/10.1016\/j.ajmo.2023.100058.","journal-title":"Am J Med Open."},{"key":"1476_CR42","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41598-018-21884-y","volume":"8","author":"HY Huang","year":"2018","unstructured":"Huang HY, Lin SY, Cheng SH, Wang CC. Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study. Sci Rep. 2018;8:3451. https:\/\/doi.org\/10.1038\/s41598-018-21884-y.","journal-title":"Sci Rep"},{"key":"1476_CR43","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1161\/strokeaha.118.024210","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function. Stroke. 2019;50:1140\u20138. https:\/\/doi.org\/10.1161\/strokeaha.118.024210.","journal-title":"Stroke"},{"key":"1476_CR44","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.amjcard.2020.01.044","volume":"125","author":"MS Cho","year":"2020","unstructured":"Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol. 2020;125:1332\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2020.01.044.","journal-title":"Am J Cardiol"},{"key":"1476_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1253\/circrep.CR-20-0026","volume":"2","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Impact of direct oral anticoagulant off-label reduced dose in combination with antiplatelet agents on clinical outcome-propensity score-matching analysis from the DIRECT real-world non-valvular atrial fibrillation registry. Circ Rep. 2020;2:289\u201396. https:\/\/doi.org\/10.1253\/circrep.CR-20-0026.","journal-title":"Circ Rep."},{"key":"1476_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ehjcvp\/pvab004","volume":"7","author":"SR Lee","year":"2021","unstructured":"Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, et al. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7:415\u201323. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab004.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1476_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/europace\/eux247","volume":"19","author":"KH Lee","year":"2017","unstructured":"Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Europace. 2017;19:1\u20139. https:\/\/doi.org\/10.1093\/europace\/eux247.","journal-title":"Europace"},{"key":"1476_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.04.084","volume":"72","author":"YC Lin","year":"2018","unstructured":"Lin YC, Chien SC, Hsieh YC, Shih CM, Lin FY, Tsao NW, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol. 2018;72:477\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.084.","journal-title":"J Am Coll Cardiol"},{"key":"1476_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40780-019-0145-3","volume":"5","author":"Y Akagi","year":"2019","unstructured":"Akagi Y, Chiba T, Uekusa S, Kato H, Yamamura S, Aoki Y, et al. Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration. J Pharmac Health Care Sci. 2019;5:1\u20137. https:\/\/doi.org\/10.1186\/s40780-019-0145-3.","journal-title":"J Pharmac Health Care Sci."},{"key":"1476_CR50","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","volume":"132","author":"R Arbel","year":"2019","unstructured":"Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132:847-855.e843. https:\/\/doi.org\/10.1016\/j.amjmed.2019.01.025.","journal-title":"Am J Med"},{"key":"1476_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","volume":"156","author":"YH Chan","year":"2019","unstructured":"Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, et al. Effectiveness and safety of four direct oral anticoagulants in asian patients with nonvalvular atrial fibrillation. Chest. 2019;156:529\u201343. https:\/\/doi.org\/10.1016\/j.chest.2019.04.108.","journal-title":"Chest"},{"key":"1476_CR52","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/strokeaha.119.025623","volume":"50","author":"WH Cheng","year":"2019","unstructured":"Cheng WH, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. Stroke. 2019;50:2574\u20137. https:\/\/doi.org\/10.1161\/strokeaha.119.025623.","journal-title":"Stroke"},{"key":"1476_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","volume":"50","author":"MS Cho","year":"2019","unstructured":"Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in asian patients with atrial fibrillation. Stroke. 2019;50:110\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.118.023093.","journal-title":"Stroke"},{"key":"1476_CR54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11239-019-01934-6","volume":"48","author":"T Ikeda","year":"2019","unstructured":"Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, et al. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. J Thromb Thrombolysis. 2019;48:653\u201360. https:\/\/doi.org\/10.1007\/s11239-019-01934-6.","journal-title":"J Thromb Thrombolysis"},{"key":"1476_CR55","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","volume":"17","author":"YH Chan","year":"2020","unstructured":"Chan YH, Chao TF, Chen SW, Lee HF, Yeh YH, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Heart Rhythm. 2020;17:2102\u201310. https:\/\/doi.org\/10.1016\/j.hrthm.2020.07.022.","journal-title":"Heart Rhythm"},{"key":"1476_CR56","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","volume":"10","author":"KN Lee","year":"2020","unstructured":"Lee KN, Choi JI, Boo KY, Kim DY, Kim YG, Oh SK, et al. Effectiveness and safety of off-label dosing of non-vitamin K Antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep. 2020;10:1801. https:\/\/doi.org\/10.1038\/s41598-020-58665-5.","journal-title":"Sci Rep"},{"key":"1476_CR57","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/cpt.1952","volume":"108","author":"M Salameh","year":"2020","unstructured":"Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, et al. Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study. Clin Pharmacol Ther. 2020;108:1265\u201373. https:\/\/doi.org\/10.1002\/cpt.1952.","journal-title":"Clin Pharmacol Ther"},{"key":"1476_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.014177","volume":"9","author":"HT Yu","year":"2020","unstructured":"Yu HT, Yang PS, Jang E, Kim TH, Uhm JS, Kim JY, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020;9: e014177. https:\/\/doi.org\/10.1161\/jaha.119.014177.","journal-title":"J Am Heart Assoc"},{"key":"1476_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000026272","volume":"100","author":"IC Chen","year":"2021","unstructured":"Chen IC, Chang WT, Hsu PC, Yeh YL, Zheng S, Huang YC, et al. Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: a retrospective, observational study. Medicine (Baltimore). 2021;100: e26272. https:\/\/doi.org\/10.1097\/md.0000000000026272.","journal-title":"Medicine (Baltimore)"},{"key":"1476_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjcard.2020.09.053","volume":"139","author":"J Ohno","year":"2021","unstructured":"Ohno J, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Dose of direct oral anticoagulants and adverse outcomes in Asia. Am J Cardiol. 2021;139:50\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2020.09.053.","journal-title":"Am J Cardiol"},{"key":"1476_CR61","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1055\/s-0042-1744543","volume":"122","author":"H Arashi","year":"2022","unstructured":"Arashi H, Yamaguchi J, Hagiwara N, Yasuda S, Kaikita K, Akao M, et al. Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings. Thromb Haemost. 2022;122:1584\u201393. https:\/\/doi.org\/10.1055\/s-0042-1744543.","journal-title":"Thromb Haemost"},{"key":"1476_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/ehjcvp\/pvad058","volume":"9","author":"YH Chan","year":"2023","unstructured":"Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9:681\u201391. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad058.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1476_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206686","author":"WR Chiou","year":"2023","unstructured":"Chiou WR, Su MI, Lee YH, Lin PL, Liu CW. Reduced-dose rivaroxaban is associated with lower all-cause mortality in older patients with nonvalvular atrial fibrillation. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12206686.","journal-title":"J Clin Med"},{"key":"1476_CR64","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pds.4778","volume":"28","author":"N Vinter","year":"2019","unstructured":"Vinter N, Linder M, Andersen M, Pedersen AB, Madsen M, Schachterle SE, et al. Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. Pharmacoepidemiol Drug Saf. 2019;28:867\u201378. https:\/\/doi.org\/10.1002\/pds.4778.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1476_CR65","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/bcp.14127","volume":"86","author":"J Santos","year":"2020","unstructured":"Santos J, Ant\u00f3nio N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86:533\u201347. https:\/\/doi.org\/10.1111\/bcp.14127.","journal-title":"Br J Clin Pharmacol"},{"key":"1476_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000525407","volume":"86","author":"MG Mosconi","year":"2023","unstructured":"Mosconi MG, Maraziti G, Paciaroni M, Giustozzi M, Vedovati MC, Bogliari G, et al. Effects of direct oral anticoagulants\u2019 nonrecommended dose in atrial fibrillation: a meta-analysis. Eur Neurol. 2023;86:13\u201324. https:\/\/doi.org\/10.1159\/000525407.","journal-title":"Eur Neurol"},{"key":"1476_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad288","author":"Y-H Chan","year":"2023","unstructured":"Chan Y-H, Chan C-Y, Chen S-W, Chao T-F, Lip GYH. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies. Europace. 2023. https:\/\/doi.org\/10.1093\/europace\/euad288.","journal-title":"Europace"},{"key":"1476_CR68","unstructured":"European Medicines Agency. CHMP Assessment Report For Xarelto. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xarelto-epar-public-assessment-report_en.pdf. 2008. Accessed 2nd March 2024."},{"key":"1476_CR69","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","volume":"70","author":"D Kubitza","year":"2010","unstructured":"Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703\u201312. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03753.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1476_CR70","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.mayocp.2020.06.057","volume":"96","author":"D Pastori","year":"2021","unstructured":"Pastori D, Menichelli D, Del Sole F, Pignatelli P, Violi F, Casciaro MA, et al. Long-term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants. Mayo Clin Proc. 2021;96:658\u201365. https:\/\/doi.org\/10.1016\/j.mayocp.2020.06.057.","journal-title":"Mayo Clin Proc"},{"key":"1476_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2018.04.036","volume":"72","author":"CJ-Y Lee","year":"2018","unstructured":"Lee CJ-Y, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M, et al. Risk of myocardial infarction in anticoagulated patients with atrial\u00a0fibrillation. J Am Coll Cardiol. 2018;72:17\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.036.","journal-title":"J Am Coll Cardiol"},{"key":"1476_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026486","volume":"9","author":"NL Pratt","year":"2019","unstructured":"Pratt NL, Ramsay E, Kalisch Ellett LM, Duszynski K, Shakib S, Kerr M, et al. Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open. 2019;9: e026486. https:\/\/doi.org\/10.1136\/bmjopen-2018-026486.","journal-title":"BMJ Open"},{"key":"1476_CR73","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","volume":"46","author":"K-L Wang","year":"2015","unstructured":"Wang K-L, Lip GYH, Lin S-J, Chiang C-E. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation. Stroke. 2015;46:2555\u201361. https:\/\/doi.org\/10.1161\/STROKEAHA.115.009947.","journal-title":"Stroke"},{"key":"1476_CR74","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","volume":"43","author":"A Zirlik","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43:365\u201379. https:\/\/doi.org\/10.1007\/s11239-016-1446-0.","journal-title":"J Thromb Thrombolysis"},{"key":"1476_CR75","doi-asserted-by":"publisher","first-page":"f11","DOI":"10.1093\/ehjcvp\/pvab002","volume":"7","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Del Sole F, Di Rocco A, Farcomeni A, Vestri A, Violi F, et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother. 2021;7:f11\u20139. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab002.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1476_CR76","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/jcm13072009","volume":"13","author":"D Poli","year":"2024","unstructured":"Poli D, Antonucci E, Ageno W, Berteotti M, Falanga A, Pengo V, et al. Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF registry. J Clin Med. 2024;13:2009.","journal-title":"J Clin Med"},{"key":"1476_CR77","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","volume":"60","author":"SR Lee","year":"2019","unstructured":"Lee SR, Lee YS, Park JS, Cha MJ, Kim TH, Park J, et al. Label Adherence For Non-Vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med J. 2019;60:277\u201384. https:\/\/doi.org\/10.3349\/ymj.2019.60.3.277.","journal-title":"Yonsei Med J"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01476-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:23:14Z","timestamp":1736335394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01476-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01476-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"7 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by University of Phayao and Thailand Science Research and Innovation Fund (Fundamental Fund 2024). The funding had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PM, NS, KP, NL, SP, LF, VS, and SS declare that they have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All data generated and analysed during this study are included in this published article (and its electronic supplementary material).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability and data transparency"}},{"value":"The Ethical Committee of the University of Phayao (UP-HEC 1.2\/023\/66) granted expedited approval for ethical considerations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No informed consent was applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PM and NS conceptualised, designed the study, and drafted the protocol. PM, KP, NL, WP performed the study selection and data extraction. KP, NL, and PM performed quality assessment while PM and SP assessed the strength of evidence. PM performed the statistical analyses. All authors were involved in interpretation of data. PM drafted the manuscript with input from all authors. All authors were involved in the critical revision of the manuscript for important intellectual content. All authors have read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}